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Sleep is a complex behavioral state that occupies one-third of the human life span. Although 
viewed as a passive condition, sleep is a highly active and dynamic process. Sleep was 
considered to be primarily important for restoration of brain function. However, to date, there 
is increasing evidence that sleep also modulates the metabolic, endocrine and cardiovascular 
systems [Trenell, 2007; Boethel, 2002; Knutson & Van Cauter, 2007; Knutson, 2008]. It is known 
that if left untreated, sleep disorders can have significant impact on daytime function, 
including learning, memory, attention, and behavior. The approach to the treatment of these 
disorders (whether with or without pharmacotherapy) is dependent on a thorough evaluation 
of the sleep complaint and accurate diagnosis. Previous studies reported a consistent 
difference between diabetic and non-diabetic subjects in the number of sleep disturbances per 
hour, indicating possible influence of diabetes on sleep pattern [Resnick, 2003; Kawakami, 
2004]. Several studies have shown that patients with T2DM sleep less than the general 
population [Vgontzas, 2000; Buxton, 2010]. A gradual decrease in self-reported sleep duration 
seems to have developed over the same period as the dramatic increase in the incidence of 
obesity and diabetes, including a close relationship between sleep cycle and diabetes [Van 
Cauter, 1997; Spiegel, 2005; Chasens, 2007; Knutson & Van Cauter, 2008]. Sleeping disorders 
related to T2DM include insomnia, restless leg syndrome, periodic leg movement disorder, 
excessive daytime sleepiness, sleepwalking, nightmares, narcolepsy, and SDB, especially SA. 
T2DM and SDB/SA are both prevalent diseases that share several risk factors, including 
advanced age and obesity [Tishler, 2003; Young, 1993]. T2DM is associated with higher 
incidence of cardiovascular, cerebrovascular, and renal diseases. There is also mounting 
evidence that SDB/SA is an independent risk factor for cardiovascular and cerebrovascular 
diseases. Interest in a potential independent link between the two diseases continues to grow. 
2. Sleep loss 
Chronic sleep loss is increasingly common in industrialized countries. The sleep impairment 
may result from various common disturbances, such as insomnia and OSA and may lead to 
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striking changes in metabolic and endocrine functions [Spiegel, 1999]. Chronic sleep loss is a 
potential risk factor for obesity, insulin resistance, and T2DM. 
Previous studies reported that both short (<6 hours) and long (>8 hours) sleepers as well as 
those with sleep loss, are at greater risk for glucose intolerance and T2DM [Sridhar & 
Madhu, 1994; Scheen, 1997; Ayas, 2003; Mallon, 2005; Gottlieb, 2005; Mallon, 2005; Yaggi, 
2006; Chaput, 2007; Nakajima, 2008].  
3. Sleep apnea 
SA is a sleep disorder characterized by pauses in breathing during sleep. There are several 
forms of SA, but the obstructive type is the commonest. In OSA, pauses in breathing are 
caused by a physical block to airflow, usually in the oropharynx. OSA is usually defined by 
interruptions of airflow of at least 10-second duration (apneas), or by a decrease in airflow 
of at least 10 seconds (hypopneas) followed by blood oxygen desaturation and arousal (brief 
arousal associated with airway opening and resumption of breathing) [Report of American 
Academy of Sleep Medicine Task Force, 1999; Masood & Phillips, 2000].  
3.1 Symptoms 
SA is often first noticed by the bed partner who witness episodes of apneas or is suspected 
based on history of habitual snoring and/or excessive daytime sleepiness, general fatigue 
or near-miss car accidents. Other symptoms reported by patients with SA include 
[Bresnitz, 1994; Gupta, 2010; Wickwire & Collop, 2010] 1) irritability, 2) poor memory, 3) 
morning headache, 4) depression, 5) mood changes, 6) sexual dysfunction, and 7) 
nocturia. 
3.2 Diagnosis 
SDB/SA is often diagnosed by an overnight cardiorespiratory test called polysomnography 
[Jafari & Mohsenin, 2010]; though other simpler methods are currently available, such as 
type 3 cardiopulmonary monitoring [Collop, 2007]. The recorded signals are analyzed for 
the numbers of apneas and hypopneas, episodes of oxygen desaturation, as well as lowest 
oxygen saturation, average oxygen saturation, and time at desaturation <90% in minutes of 
the total bedtime for the entire night. Apnea is defined as a decrease in the amplitude of the 
airflow or respiratory effort signal to <10% of the baseline lasting at least 10 seconds. 
Hypopnea is defined as a decrease in the airflow or respiratory effort to <70% of the baseline 
for at least 10 seconds accompanied by >4% fall in oxygen saturation. The apnea-hypopnea 
index (AHI) is defined as the number of apneas/hypopneas per hour of sleep time. The 
latter is measured from the recorded signals of the electroencephalogram (averaged brain 
activity), electrooculogram (eye movements) and nuchal muscles electromyogram. An AHI 
of 5 establishes the diagnosis of SDB/SA. OSA is defined as absence of airflow in the 
presence of chest wall and/or abdominal excursions. The severity of SA is based on the 
AHI, and classified as mild (AHI ≥5 to <15), moderate (AHI ≥15 to <30), and severe (AHI 
≥30), according to the guidelines of the American Academy of Sleep Medicine Task Force 
[Report of American Academy of Sleep Medicine Task Force, 1999]. 
3.3 Clinical features 
Obese patients with OSA have short and wide neck, large tongue, and excess pharyngeal 
soft tissues. Significant SA is present in 40% of obese individuals, and 70% of OSA patients 
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are obese [Vgontzas AN, 1994; Resta O, 2001; Daltro C, 2007]. Not only excess weight but 
also fat distribution, i.e. intra-abdominal fat accumulation, plays a major role in the 
development of OSA [Shinohara, 1997; Schäfer, 2002; Vgontzas, 2003]. A recent study of 
Japanese patients with T2DM found that BMI and waist circumference (WC) were the 
strongest predictors of the severity of SDB [Kashine, 2011]. OSA is independently associated 
with insulin resistance, T2DM and hypertension [Idris, 2009]. Several reports found high 
incidence of SA in both Japanese [Katsumata, 1991] and Caucasian [Einhorn, 2007] diabetic 
patients. 
3.4 Treatment 
There are several options for treatment of SA [Rosenberg & Doghramji, 2009]. These include: 
3.4.1 Lifestyle changes 
Weight loss, especially visceral fat reduction through caloric diet and exercise, should be 
recommended for all overweight patients with SA. Avoidance of alcohol and sleeping pills 
is often beneficial. 
3.4.2 Oral devices 
Oral devices such as dental appliances have been used with some success to maintain an 
open airway during sleep [Ng, 2005].  
3.4.3 Nasal Continuous Positive Airway Pressure (nCPAP) 
Nasal continuous positive airway pressure (nCPAP) is the golden standard treatment of SA 
in which a mask is worn over the nose and/or mouth whilst sleeping. The mask is attached 
to a machine that delivers a continuous stream of compressed air. The positive pressure 
pneumatically maintains an open airway during sleep. Treatment of OSA is reported to 
improve daytime sleepiness and various other clinical features of Sa including insulin 
responsiveness [Hassaballa, 2005; Harsch, 2004]. 
3.4.4 Surgery 
Surgery may be considered in some cases, particularly those with tonsillar and adenoidal 
hypertrophy, narrow nasal airways, or facial deformities such as small jaw, nasal polyp or 
deviated nasal septum [Sundaram, 2005; Lojander, 1996; Holty, 2010].  
4. Type 2 diabetes and sleep apnea 
SDB/SA is often observed in patients with T2DM, and known to be potentially associated 
with atherosclerosis, leading to ACVDs. The International Diabetes Federation (IDF) 
Taskforce on Epidemiology and Prevention [Shaw, 2008] stated that the pathophysiological 
consequences of hypoxemia and sleep fragmentation might be involved in the development 
of insulin resistance and pancreatic -cell dysfunction through various biological 
mechanisms, such as direct effects of 1) intermittent hypoxia/desaturation and hypoxemia, 
2) sympathetic nervous system activation (catecholamine) [Prabhakar & Kumar, 2010; Esler 
& Eikelis, 2006], 3) systemic inflammation (tumor necrosis factor-alpha [TNF-], interluokin-
6 [IL-6], high sensitivity C-reactive protein [hsCRP] and monocyte chemoattractant protein 1 
[MCP-1]) [Drager, 2010; Sahlman, 2010; Romero-Corral, 2010], 4) hypothalamic-pituitary-
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adrenal dysfunction (cortisol) [Follenius, 1992; Henley, 2009; Vgontzas & Chrousos, 2002], 5) 
dysregulation of adipocytokines (plasminogen activator inhibitor-1 [PAI-1], adiponectin) 
[Lam, 2008], 6) sleep architecture [Wang & Teichtahl, 2007] and 7) other factors. Both 
SDB/SA and T2DM are strongly associated with ACVD [Bradley & Floras, 2009] (Figure 1). 
 
 
Fig. 1. Relationships among sleep-disordered breathing, visceral fat accumulation and 
atherosclerosis. 
5. Type 2 diabetes mellitus and sleep-disordered breathing / sleep apnea: 
Role of adipocytokines 
Both T2DM and SDB/SA have been linked to the metabolic syndrome based on visceral fat 
accumulation, with clustering of hyperglycemia, intra-abdominal fat accumulation, 
hypertension, hypertriglyceridemia, and hypo-high-density-lipoprotein-cholesterolemia 
[Rasche, 2010; Lui & Ip, 2010]. There is a broad overlap between the presumed mechanisms 
of that link T2DM and SDB/SA and features of the metabolic syndrome (Syndrome X) 
[Reaven, 1993], which is also known as “Syndrome Z” [Wilcox, 1998].  
In addition to the localization and functional properties of visceral fat, experimental 
evidence links certain molecules in visceral fat to human disorders, especially insulin 
resistance and ACVD. An important question relates to the profile of molecules or genes 
expressed in subcutaneous and visceral fat. In order to answer this question, our group in 
collaboration with the human body map project team investigated the gene expression 
profile in human adipose tissue. This tissue had been traditionally regarded as a passive 
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storage of excess energy in the form of triglycerides. Unexpectedly, we found that adipose 
tissues, especially visceral fat, abundantly express genes that encode secretory proteins 
including complement factors in the immune system, growth factors, and cytokines, most of 
which are important bioactive substances [Maeda, 1997; Matsuzawa, 2004]. We found PAI-1 
[Shimomura, 1996] and HB-EGF [Matsumoto, 2002] in human visceral and subcutaneous fat 
cDNA library. Excess visceral fat overproduces and secretes PAI-1, which in turn increases 
the risk for thrombotic disorders [Shimomura, 1996]. Thus, it seems that visceral fat is 
directly linked to ACVD. Adipose tissue also produces a variety of the bioactive substances 
conceptualized as ‘adipocytokines’ [Funahashi, 1999; Matsuzawa, 2010]. Through systematic 
analysis of adipose tissue-expressed genes, we discovered a novel gene, designated adipose 
most abundant gene transcript 1 (apM1), for an adipocyte-derived secretory protein [Maeda, 
1996], which was later named ‘adiponectin’. At the same time, using different approaches, 
adiponectin was identified independently by three other groups, as adipocyte complement-
related protein of 30 kDa (ACRP30) [Scherer, 1995], adipoQ [Hu, 1996], and gelatin binding 
protein of 28 kDa (GBP28) [Nakano, 1996]. Adiponectin is specifically expressed in the 
adipose tissue [Arita, 1999]. The molecule has two domains, namely a collagen-like fibrous 
domain and a C1q-like globular domain. The single molecules combine and form a high-
ordered structure [Arita, 1999]. Adiponectin binds to collagens I, III, and V, which are 
present in the subendothelial intima [Okamoto, 2000]. In fact, adiponectin adheres to 
endothelium-injured arterial walls [Okamoto, 2000]. This is the reason why we named this 
protein ‘adiponectin’ [Arita, 1999]. Numerous experimental studies found that adiponectin 
has anti-atherosclerotic [Ouchi, 2003] and insulin sensitivity properties [Han, 2009]. 
The production and secretion of adipocytokines are dynamically regulated by nutritional 
status. Over-eating and physical inactivity result in visceral fat accumulation, which leads to 
visceral fat dysfunction and dysregulated production of adipocytokines (overproduction of 
offensive adipocytokines, such as PAI-1, TNF-, HB-EGF and angiotensinogen, and 
underproduction of defensive adipocytokines, such as adiponectin), a state we call 
adipotoxicity. These changes are probably the major underlying mechanisms of lifestyle-
related diseases [Kishida, 2011].  
Daytime hypoadiponectinemia and nocturnal falls in circulating adiponectin concentrations in 
OSA patients with abdominal obesity, are in part, due to hypoxic stress [Nakagawa, 2008 & 
2011]. A high frequency of SDB was identified in Japanese patients with poorly controlled 
T2DM, who also had intra-abdominal obesity with nocturnal dysregulated production of 
adiponectin [Kashine, 2010]. Obese East and South Asians including Japanese have a mild 
degree of adiposity, compared with European and American subjects [Wulan, 2010; Fujimoto, 
1999; Tong, 2007; Kadowaki, 2006]. Unlike total body fat, body fat distribution, especially 
excess accumulation of visceral fat, correlates with various diabetogenic, atherogenic, 
prothrombotic and proinflammatory metabolic abnormalities in Japanese (referred to as the 
metabolic syndrome), that increase the risk of ACVD [Fujioka, 1987; Matsuzawa, 1994].  
6. Conclusion 
It is necessary to diagnose SDB from the standpoint of prevention of ACVD in diabetic 
patients. Weight reduction, particularly reduction of visceral fat, intensive glucose-lowering 
therapy, nCPAP therapy, or the combination of these therapies, have beneficial effects on 
the outcome of T2DM patients with SDB through improvement of dysregulated production 
of adipocytokines and SDB-related ACVD.  
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